Category: Clinical Trial Design and Research Terminology
Recommended Phase 2 Dose
The dose selected for further evaluation in later-stage clinical studies based on available safety, pharmacokinetic, pharmacodynamic, and other relevant evidence. In DMD development, selecting this dose involves balancing potential therapeutic activity with tolerability and the risks of treatment.
- Abbreviation:
- RP2D
- Updated November 3, 2026